Azenta (AZTA) AI Stock Analysis

• Market Cap: $1.30B
• Dividend Yield: N/A
• Average Volume (3M): 913.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: -8.15%
• EPS Growth: 13.50%
• Country: US
• Employees: 3,000
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.19
• Shares Outstanding: 45,839,730
• 10 Day Avg. Volume: 795,162
• 30 Day Avg. Volume: 913,250
• PEG Ratio: -0.01
• Price to Book (P/B): 1.46
• Price to Sales (P/S): 3.92
• P/FCF Ratio: 199.72
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 1.89
• Enterprise Value/Gross Profit: 4.20
• Enterprise Value/Ebitda: 31.49
• 1Y Price Target: $34.60
• Price Target Upside: 28.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 51 Neutral
• Price Target: $29.00 ▲(7.81% Upside)

Azenta's overall stock score is driven by financial performance challenges, including declining revenues and profitability issues, despite a strong balance sheet. The earnings call provided some positive insights, but technical analysis and valuation concerns weigh heavily on the score.

Positive Factors

Partnerships and Expansion

A new partnership in cell and gene therapy expands Azenta's business portfolio and enhances growth opportunities.

Profitability and Growth Strategy

Azenta's strategy includes significant investments in product differentiators like next-gen automation, which is expected to drive long-term growth.

Strategic Restructuring

The new management team has initiated a strategic restructuring to focus on higher margin segments, which is seen as a necessary move for future growth.

Negative Factors

Geopolitical Tensions

China is expected to remain a double-edged sword that could keep Azenta at a higher risk of exposure if geopolitical tensions continue.

NIH Funding and Trade Concerns

Uncertainties around NIH funding and trade tensions with China are significant concerns for investors due to Azenta's exposure in the multiomics segment.

Vaccine Cold Chain Challenges

The company is facing significant geopolitical tensions and challenges in the vaccine cold chain segment, which have been major obstacles in recent months.

Azenta Business Overview & Revenue Model

Company Description

Azenta, Inc. (AZTA) is a leading provider of life sciences solutions, catering to areas such as genomics, cryogenic storage, and automation. The company offers comprehensive services to support the life sciences industry, including sample management, genomic services, and automated storage systems. Azenta is committed to advancing scientific research and discovery by providing innovative solutions that enhance laboratory efficiency and operational productivity.

How the Company Makes Money

Azenta generates revenue primarily through its diversified portfolio of life sciences solutions and services. Key revenue streams include the provision of genomic services, which involve sequencing and analytical services to assist researchers in understanding genetic information. Another significant source of income is the company's sample management services, which encompass storage, transport, and management of biological samples under highly controlled conditions. Additionally, Azenta offers automation systems designed to streamline laboratory processes, further contributing to its revenue. Strategic partnerships with research institutions, pharmaceutical companies, and biotechnology firms play a crucial role in driving sales and expanding its market reach.

Azenta Financial Statement Overview

Summary

Azenta demonstrates strong financial stability with a solid equity position and low leverage. However, ongoing profitability challenges are reflected in negative margins and declining revenues. While cash flow management shows positive signs, the overall financial health is impacted by losses and inefficiencies in generating returns.

Income Statement

Azenta's income statement reveals declining revenue with a negative trend in profitability. The TTM (Trailing-Twelve-Months) gross profit margin stands at 43%, which indicates a reasonable ability to control production costs. However, the company has faced significant challenges with negative net and EBIT margins, reflecting ongoing struggles with profitability. There is a concerning downward trend in revenue growth, leading to an overall weak income statement performance.

Balance Sheet

The balance sheet shows a strong equity base with low leverage, indicated by a debt-to-equity ratio of 0.03 in the TTM. The equity ratio of 83% highlights financial stability and strong asset backing. However, the return on equity remains negative due to ongoing net losses, indicating inefficiencies in generating profits from shareholders' equity.

Cash Flow

Azenta's cash flow statement shows positive operating cash flow in the TTM, which is a positive indicator of potential liquidity. The free cash flow has improved, showing growth, but the operating cash flow to net income ratio indicates challenges in converting net income into cash. Despite some positive movements, cash flow generation remains a concern amidst profitability issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	604.93M	656.32M	665.07M	555.50M	513.70M	897.27M
Gross Profit	271.73M	263.37M	263.14M	255.58M	243.81M	380.02M
EBITDA	36.22M	17.85M	55.15M	48.35M	9.94M	28.15M
Net Income	-111.59M	-164.17M	-14.26M	-11.29M	-28.87M	64.85M
Balance Sheet
Total Assets	2.02B	2.10B	2.89B	3.72B	1.82B	1.56B
Cash, Cash Equivalents and Short-Term Investments	318.86M	462.09M	1.02B	1.57B	227.51M	295.72M
Total Debt	52.63M	70.68M	60.44M	49.23M	94.77M	82.27M
Total Liabilities	345.50M	331.07M	351.22M	352.74M	494.18M	345.51M
Stockholders Equity	1.67B	1.77B	2.53B	3.36B	1.33B	1.21B
Cash Flow
Free Cash Flow	45.67M	12.90M	-21.95M	-543.48M	97.05M	-2.06M
Operating Cash Flow	83.72M	50.29M	17.49M	-466.05M	149.86M	37.87M
Investing Cash Flow	104.05M	224.74M	431.38M	1.47B	-146.35M	-22.74M
Financing Cash Flow	-257.95M	-659.21M	-844.08M	-62.76M	-25.91M	-27.02M

Azenta Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 26.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Negative. The current price of 26.9 is below the 20-day moving average (MA) of 32.17, below the 50-day MA of 30.97, and below the 200-day MA of 38.49, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 40.37 is Neutral, neither overbought nor oversold. The STOCH value of 19.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTA.

Azenta Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRC	68 Neutral	$1.82B	―	-7.85%	―	16.28%	10.63%
ICUI	65 Neutral	$3.12B	―	-4.62%	―	7.19%	-56.19%
STAA	63 Neutral	$1.33B	55.81	-25.55%	―	-14.44%	-557.38%
BLFS	59 Neutral	$991.62M	―	-3.29%	―	-23.12%	97.46%
Sector *	51 Neutral	$7.39B	0.36	-62.86%	2.37%	15.48%	-2.68%
AZTA	51 Neutral	$1.30B	―	-1.74%	―	-8.15%	13.50%
QDEL	50 Neutral	$1.60B	―	-14.80%	―	-3.04%	76.48%

Azenta Corporate Events

Azenta Announces Resignation of Chief Accounting Officer

On June 27, 2025, Azenta, Inc. announced the resignation of Violetta Hughes, Vice President and Chief Accounting Officer, effective August 6, 2025. Her departure is amicable and not due to any disagreements with the company’s operations or policies, ensuring a smooth transition of responsibilities.

The most recent analyst rating on (AZTA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.

Azenta Announces Leadership Change with New General Counsel

On May 12, 2025, Azenta, Inc. announced that Jason W. Joseph, Senior Vice President, General Counsel, and Secretary, will step down from his role effective May 15, 2025, with his employment ending on June 30, 2025. In return for a release of claims and consulting services, Joseph will receive benefits including accelerated vesting of stock units and continued vesting of equity awards. Ephraim Starr has been appointed to succeed Joseph, bringing extensive experience from roles at Lean Focus, LLC, PHC Holdings Corporation, and Danaher Corporation.

The most recent analyst rating on (AZTA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.